Tg Therapeutics (TGTX) Receivables - Net (2021 - 2025)
Tg Therapeutics (TGTX) has 5 years of Receivables - Net data on record, last reported at $305.6 million in Q4 2025.
- For Q4 2025, Receivables - Net rose 136.58% year-over-year to $305.6 million; the TTM value through Dec 2025 reached $305.6 million, up 136.58%, while the annual FY2025 figure was $305.6 million, 136.58% up from the prior year.
- Receivables - Net reached $305.6 million in Q4 2025 per TGTX's latest filing, up from $265.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $305.6 million in Q4 2025 and bottomed at $88000.0 in Q2 2022.
- Average Receivables - Net over 5 years is $83.8 million, with a median of $45.2 million recorded in 2023.
- Peak YoY movement for Receivables - Net: plummeted 90.55% in 2022, then skyrocketed 19768.18% in 2023.
- A 5-year view of Receivables - Net shows it stood at $1.4 million in 2021, then plummeted by 93.66% to $88000.0 in 2022, then soared by 57960.23% to $51.1 million in 2023, then skyrocketed by 152.84% to $129.2 million in 2024, then skyrocketed by 136.58% to $305.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $305.6 million in Q4 2025, $265.4 million in Q3 2025, and $231.5 million in Q2 2025.